Tyche Industries Ltd
Incorporated in 1998, Tyche Industries Ltd
does manufacturing of active pharmaceutical ingredients[1]
- Market Cap ₹ 108 Cr.
- Current Price ₹ 106
- High / Low ₹ 148 / 99.0
- Stock P/E 24.3
- Book Value ₹ 137
- Dividend Yield 2.84 %
- ROCE 6.83 %
- ROE 5.01 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.77 times its book value
- Company has been maintaining a healthy dividend payout of 32.5%
Cons
- The company has delivered a poor sales growth of -7.28% over past five years.
- Company has a low return on equity of 8.05% over last 3 years.
- Earnings include an other income of Rs.9.72 Cr.
- Debtor days have increased from 110 to 133 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63.86 | 54.08 | 42.61 | 51.60 | 53.95 | 73.70 | 78.24 | 62.27 | 75.39 | 69.51 | 65.47 | 53.63 | 50.04 | |
| 56.80 | 51.16 | 36.62 | 42.57 | 44.78 | 52.31 | 53.52 | 51.30 | 59.24 | 56.86 | 54.19 | 51.39 | 51.44 | |
| Operating Profit | 7.06 | 2.92 | 5.99 | 9.03 | 9.17 | 21.39 | 24.72 | 10.97 | 16.15 | 12.65 | 11.28 | 2.24 | -1.40 |
| OPM % | 11.06% | 5.40% | 14.06% | 17.50% | 17.00% | 29.02% | 31.60% | 17.62% | 21.42% | 18.20% | 17.23% | 4.18% | -2.80% |
| 0.25 | 1.68 | 1.89 | 1.69 | 2.52 | 3.68 | 3.75 | 3.46 | 4.71 | 5.92 | 7.42 | 9.22 | 9.72 | |
| Interest | 1.11 | 0.29 | 0.08 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 3.34 | 1.76 | 1.87 | 1.85 | 1.84 | 1.74 | 1.72 | 1.79 | 1.77 | 1.94 | 1.99 | 2.00 | 2.16 |
| Profit before tax | 2.86 | 2.55 | 5.93 | 8.86 | 9.85 | 23.33 | 26.74 | 12.64 | 19.09 | 16.63 | 16.71 | 9.46 | 6.16 |
| Tax % | 32.87% | 3.53% | 48.06% | 33.86% | 27.41% | 24.73% | 25.24% | 26.11% | 25.72% | 26.40% | 25.73% | 26.74% | |
| 1.93 | 2.47 | 3.08 | 5.86 | 7.15 | 17.56 | 19.98 | 9.33 | 14.17 | 12.24 | 12.41 | 6.94 | 4.45 | |
| EPS in Rs | 1.88 | 2.41 | 3.00 | 5.72 | 6.98 | 17.13 | 19.49 | 9.10 | 13.82 | 11.94 | 12.11 | 6.77 | 4.34 |
| Dividend Payout % | 26.50% | 20.71% | 16.61% | 8.75% | 7.17% | 0.00% | 5.13% | 16.48% | 0.00% | 20.94% | 24.78% | 51.69% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -7% |
| 3 Years: | -11% |
| TTM: | -21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -20% |
| 3 Years: | -21% |
| TTM: | -65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -10% |
| 3 Years: | -15% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | 8% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.23 | 10.23 | 10.23 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 |
| Reserves | 33.56 | 35.36 | 37.66 | 42.88 | 50.02 | 66.93 | 85.72 | 93.97 | 106.51 | 116.49 | 126.46 | 130.23 |
| 8.68 | 10.83 | 0.00 | 0.07 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 11.51 | 11.01 | 13.10 | 13.52 | 13.70 | 17.52 | 20.98 | 16.05 | 19.95 | 7.95 | 10.69 | 7.56 | |
| Total Liabilities | 63.98 | 67.43 | 60.99 | 66.72 | 74.01 | 94.70 | 116.95 | 120.27 | 136.71 | 134.69 | 147.40 | 148.04 |
| 28.98 | 28.40 | 26.57 | 19.84 | 19.15 | 17.67 | 17.93 | 16.63 | 16.61 | 17.90 | 16.48 | 18.88 | |
| CWIP | 0.38 | 0.33 | 0.33 | 0.00 | 0.00 | 0.00 | 0.53 | 0.00 | 0.00 | 0.00 | 0.16 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 34.62 | 38.70 | 34.09 | 46.88 | 54.86 | 77.03 | 98.49 | 103.64 | 120.10 | 116.79 | 130.76 | 129.16 | |
| Total Assets | 63.98 | 67.43 | 60.99 | 66.72 | 74.01 | 94.70 | 116.95 | 120.27 | 136.71 | 134.69 | 147.40 | 148.04 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.31 | 11.96 | 11.37 | 5.04 | 3.75 | 15.21 | 15.45 | 4.46 | 6.43 | 7.71 | 8.54 | 2.85 | |
| -0.98 | -1.34 | 0.60 | 6.29 | 0.63 | 2.04 | 0.42 | 3.16 | -3.12 | 3.94 | -0.62 | -8.95 | |
| -3.24 | 1.59 | -10.59 | -0.60 | -0.07 | -0.62 | -1.02 | -1.02 | -1.54 | -2.05 | -2.56 | -3.07 | |
| Net Cash Flow | -1.90 | 12.20 | 1.38 | 10.72 | 4.31 | 16.63 | 14.85 | 6.59 | 1.77 | 9.61 | 5.37 | -9.17 |
| Free Cash Flow | 1.33 | 10.82 | 11.33 | 10.25 | 2.61 | 14.95 | 12.95 | 4.58 | 4.68 | 4.48 | 7.84 | -1.41 |
| CFO/OP | 33% | 410% | 190% | 56% | 41% | 71% | 62% | 41% | 40% | 61% | 76% | 127% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 90.65 | 106.71 | 81.12 | 68.05 | 68.81 | 64.04 | 79.91 | 96.25 | 106.90 | 100.40 | 95.45 | 132.99 |
| Inventory Days | 138.26 | 67.76 | 83.68 | 85.37 | 122.85 | 121.71 | 148.08 | 148.32 | 195.21 | 157.11 | 244.61 | 149.93 |
| Days Payable | 75.69 | 92.82 | 130.50 | 86.81 | 95.79 | 91.41 | 93.04 | 77.86 | 134.49 | 47.91 | 85.26 | 37.78 |
| Cash Conversion Cycle | 153.22 | 81.65 | 34.30 | 66.61 | 95.87 | 94.34 | 134.95 | 166.71 | 167.62 | 209.60 | 254.79 | 245.13 |
| Working Capital Days | 77.39 | 21.46 | 60.48 | 66.63 | 86.53 | 77.11 | 82.76 | 121.22 | 128.74 | 144.30 | 150.86 | 177.43 |
| ROCE % | 7.37% | 5.22% | 11.52% | 17.55% | 17.36% | 33.92% | 32.04% | 13.32% | 17.39% | 13.66% | 12.67% | 6.83% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Electricity Consumption Lakh KWH |
|
||||||||
| Export Revenue Share % |
|||||||||
| Husk Consumption MT |
|||||||||
| R&D Expenditure Rs Lakhs |
|||||||||
| Number of Permanent Employees count |
|||||||||
| R&D Personnel Count count |
|||||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Publication_ Unaudited Financial Results for the quarter ended June 30, 2026.
-
Unaudited Financial Results For The Quarter Ended June 30, 2026
- Board approved Q1 FY27 unaudited results; profit ₹4.17 lakh loss, auditors qualified revenue recognition by ₹160.43 lakh.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 11Th August, 2026
- Tyche Industries approved Q1 FY27 results; auditors qualified revenue recognition, overstating profit by Rs48.64 lakh.
-
Board Meeting Intimation for Approval Of Un-Audited Financial Results For The 1St Quarter Ended 30Th June, 2026.
- Board meeting on 11 August 2026 to approve Q1 FY2026-27 unaudited results; trading window closed from 1 July.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper advertisement for the transfer of equity shares of the Company to IEPF pursuant to IEPFA(Accounting, Audit, Transfer and Refund) Rules, 2016
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Company is a manufacturer and exporter of APIs, Intermediates and Nutraceuticals. It is one of the largest Indian manufacturers of Glucosamine Hydrochloride and corresponding sodium and potassium salts which are mainly exported to USA and Europe